How CV Sciences Inc (OTCMKTS:CVSI) Has Retaken Control Over Its Narrative

How CV Sciences Inc (OTCMKTS:CVSI) Has Retaken Control Over Its Narrative

SHARE

One stock that is back from the abyss (as we have consistently predicted) is CV Sciences Inc (OTCMKTS:CVSI). This was a “victim” of a shortseller attack – as we see it – back in August, but has held up well with consistent sales growth data resuming a dominant position over the narrative. To further flesh out the story, the company just announced that it has received Nutritional Outlook’s 2018 Best of the Industry Awards, Retail/Brand Product, for the Company’s best-selling PlusCBD Oil line of hemp-derived CBD products.

Editor-in-Chief Jennifer Grebow states, “In Nutritional Outlook’s 2018 Best of the Industry Awards, we are recognizing individuals, groups, and companies whose initiatives today may help shape, for the better, the state of the dietary supplement and food and beverage industries for years to come.”

CV Sciences Inc (OTCMKTS:CVSI) bills itself as a life science company, focuses on developing and commercializing novel therapeutics utilizing synthetic Cannabidiol (CBD).

CVSI operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors, including nutraceutical, beauty care, specialty foods, and vape.

Following the CanX Acquisition in December 2015, CV Sciences commenced its preclinical drug development program during the second quarter of 2016. The Company’s drug development efforts include pursuing synthetic-based Cannabidiol drug candidates in areas that have the potential to provide significant improvements in therapeutic patient treatments with sizable addressable markets.

The company was formerly known as CannaVEST Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California.

CV Sciences Inc is led by Michael J. Mona, JR. founder of CV Sciences, Mr. Mona possesses over 30 years of senior management experience in a range of industries including real estate/construction, industrial farming, chemical processing and consumer products. Mr. Mona is a recognized industry leader in hemp farming operations and chemical extraction and has established a global supply chain of hemp-derived products.

According to company materials, “CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada and San Diego, California.”

Find out when $CVSI reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

As noted above, CVSI just announced that it has received Nutritional Outlook’s 2018 Best of the Industry Awards, Retail/Brand Product, for the Company’s best-selling PlusCBD Oil line of hemp-derived CBD products.

Traders will note 16% tacked on to share pricing for the listing in the past week. Furthermore, the name has witnessed a pop in interest, as transaction volume levels have recently pushed 22% beyond what we have been seeing over the larger time frame.

“Nutritional Outlook has been on the forefront of the nutraceutical industry, providing news and insight to over 200,000 industry professionals,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “We are pleased to be honored amongst fellow industry stalwarts for our commitment to building consumer confidence and trust in the safety and quality of our products.

Earning a current market cap value of $515.69M, CVSI has a significant war chest ($11M) of cash on the books, which compares with about $3M in total current liabilities. CVSI is pulling in trailing 12-month revenues of $41.3M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 143.3%. We will update the story again soon as further details emerge. Sign-up for continuing coverage on shares of $CVSI stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $CVSI, either long or short, and we have not been compensated for this article.

Sign Up for our 100% FREE Oracle Dispatch Newsletter